Many mergers have been announced or have closed, but just seven recent and pending deals have transformed how analysts and investors alike are having to view corporate America.
The August 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The top analyst upgrades, downgrades and initiations for Tuesday included Amgen, BorgWarner, Chipotle Mexican Grill, Cree, Dollar General, Exelon, PDC Energy, Verizon Communications and Zynga.
Both Amgen and Celgene shares made a handy gain on Monday after it was announced that the companies had made an agreement in relation to Celgene’s merger with Bristol-Myers Squibb.
The top analyst upgrades, downgrades and initiations for Monday included Amgen, Aramark, Chevron, Deere, Exxon Mobile, Hecla Mining, Occidental Petroleum, Urban Outfitters and Whiting Petroleum.
The top analyst upgrades, downgrades and initiations on Friday included Alibaba, Amgen, Applied Materials, Intel, Merck, Nvidia and Walmart.
24/7 Wall St. has evaluated all pharmaceutical and biotech companies that pay dividend yields above 2% based on their current prices.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Amgen shares rose early Wednesday after it released better than expected second-quarter financial results late on Tuesday.
Chris Lange The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most…
The June 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The May 31 short interest data have been compared with the previous report, and short interest in most…
Amgen is the largest of all biotechs now, and it is being deemed an "ASCO winner" for cancer and oncology news. At least, that is the view of Credit Suisse.
Jon C. Ogg The May 15 short interest data have been compared with the previous report, and short interest in most of these selected biotech stocks increased.